We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FCEL icon
351
FuelCell Energy
FCEL
$1.89B
$92.4K ﹤0.01%
2,588
-348
-12% -$12.8K
AKBA icon
352
Akebia Therapeutics
AKBA
$362M
$86.2K ﹤0.01%
+47,100
New +$75.3K
QSIAW
353
DELISTED
Quantum-Si Inc Warrant
QSIAW
$80.7K ﹤0.01%
333,333
– –
PAYO icon
354
Payoneer
PAYO
$2.42B
$77.6K ﹤0.01%
+15,974
New +$77.8K
NUVB.WS
355
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$50.4K ﹤0.01%
166,666
– –
DNA icon
356
Ginkgo Bioworks
DNA
$528M
$40.6K ﹤0.01%
+874
New +$45.2K
BFLY.WS
357
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$33.1K ﹤0.01%
733,333
– –
WW
358
DELISTED
WW International
WW
$26.9K ﹤0.01%
+14,549
New +$57.9K
CMAXW
359
DELISTED
CareMax, Inc. Warrant
CMAXW
$11.5K ﹤0.01%
672,000
– –
SRZNW icon
360
Surrozen Inc Warrant
SRZNW
$69.7K
$5.03K ﹤0.01%
166,666
– –
TLSI icon
361
TriSalus Life Sciences
TLSI
$280M
$10 ﹤0.01%
1
– –
ACAD icon
362
Acadia Pharmaceuticals
ACAD
$4.55B
– –
-9,728
Closed -$305K
ADM icon
363
Archer Daniels Midland
ADM
$38.9B
– –
-3,742
Closed -$270K
ALLO icon
364
Allogene Therapeutics
ALLO
$680M
– –
-28,169
Closed -$90.4K
ALNY icon
365
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-1,574
Closed -$301K
OSG
366
Octave Specialty Group
OSG
$250M
– –
-12,673
Closed -$209K
ANDE icon
367
Andersons Inc
ANDE
$2.44B
– –
-8,517
Closed -$490K
APLD icon
368
Applied Digital
APLD
$8.05B
– –
-16,779
Closed -$113K
AROC icon
369
Archrock
AROC
$6.21B
– –
-21,524
Closed -$331K
ARVN icon
370
Arvinas
ARVN
$536M
– –
-6,419
Closed -$264K
AVGO icon
371
Broadcom
AVGO
$1.85T
– –
-1,800
Closed -$201K
AVXL icon
372
Anavex Life Sciences
AVXL
$250M
– –
-14,654
Closed -$136K
AVY icon
373
Avery Dennison
AVY
$13.4B
– –
-1,805
Closed -$365K
BDN
374
Brandywine Realty Trust
BDN
$525M
– –
-46,297
Closed -$250K
BMEA icon
375
Biomea Fusion
BMEA
$88.2M
– –
-11,206
Closed -$163K
13 14
15
16 17

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.